Clinical trials: Cell Transplantation
Bone Marrow Transplantation, Graft vs Host Disease
T-Cell Depletion in Unrelated Donor Marrow Transplantation
To determine if a reduction in morbidity and mortality from acute and chronic graft versus host disease (GvHD) can be achieved through use of T-cell depletion techniques without a counterbalancing increase in relapse of leukemia…
- Conditions
- Bone Marrow Transplantation, Graft vs Host Disease, Immunologic Diseases, Leukemia
- Trial name
- NCT00000591
- Testing
- lymphocyte depletion
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Diffuse, Large B-Cell, Lymphoma
Phase II Study With Ga101-DHAP as Induction Therapy in Relapsed/Refractory DLBCL Patients
Aim of this trial is to assess the efficacy of new anti-CD20 antibody (GA101) in association with DHAP as induction therapy before high dose chemotherapy BEAM with ASCT in patients with relapsed/refractory DLBCL.
- Trial name
- GIOTTO (NCT02374424)
- Testing
- GA101_DHAP
- Where
- 10 sites in Italy
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- Fondazione Italiana Linfomi - ETS
Respiratory Syncytial Virus Infections
Anti-viral Effect of PC786 on RSV Infection on HSCT Recipients
This study tests the effects of an experimental drug PC786 in people infected with Respiratory Syncytial Virus (RSV). PC786 may be useful in treating patients infected with RSV as it works by interfering with the way the virus…
- Trial name
- TreatRSV1 (NCT03715023)
- Testing
- PC786, SOC
- Where
- 7 sites in United Kingdom
- Volunteers
- 5 people
- Sponsor
- Pulmocide Ltd
Leukemia, Myelocytic, Acute
Reduced Intensity Regimen vs Myeloablative Regimen for Myeloid Leukemia or Myelodysplastic Syndrome (BMT CTN 0901)
The study is designed as a Phase III, multicenter trial comparing outcomes after allogeneic hematopoietic stem cell transplantation (HCT) for acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) between patients…
- Trial name
- NCT01339910
- Testing
- Fludarabine and Busulfan, Fludarabine and Melphalan, Busulfan and Fludarabine
- Where
- 32 sites in United States
- Volunteers
- 272 people
- Sponsor
- Medical College of Wisconsin
Hematopoietic Stem Cell Transplantation, Graft vs Host Disease
Evaluation of Immunoregulatory Cells in Hematopoietic Stem Cell Transplant
The investigators' hypothesis is that the graft-versus-tumor effect can be enhanced while minimizing the complications of graft-versus-host disease.
- Trial name
- NCT00179049
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Vanderbilt University
Adult Grade III Lymphomatoid Granulomatosis, Cutaneous B-cell Non-Hodgkin Lymphoma
Genetically Modified T-cell Infusion Following Peripheral Blood Stem Cell Transplant in Treating Patients With Recurrent or High-Risk Non-Hodgkin Lymphoma
This phase I trial studies the side effects and best dose of genetically modified T-cells following peripheral blood stem cell transplant in treating patients with recurrent or high-risk non-Hodgkin lymphoma.
- Conditions
- Adult Grade III Lymphomatoid Granulomatosis, Cutaneous B-cell Non-Hodgkin Lymphoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Intraocular Lymphoma
- Trial name
- NCT01815749
- Testing
- autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T cells, autologous hematopoietic stem cell transplantation, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- City of Hope Medical Center
Cytomegalovirus Infection, Infection
Comparison of Two Test Methods-NASBA and Antigenemia-for Detecting Cytomegalovirus Infection
This study will evaluate the reliability of a new test called Real-Time Polymerase chain reaction (RT PCR) in detecting cytomegalovirus (CMV) in the blood and predicting the course of CMV disease in patients who have recently had…
- Trial name
- NCT00001976
- Where
- United States
- Volunteers
- 180 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Newly Diagnosed Multiple Myeloma, Multiple Myeloma
Dara-RVd Induction for Newly Diagnosed Multiple Myeloma With Autologous Stem Cell Transplantation
This Phase II hybrid decentralized trial will examine the effect of daratumumab-based quadruplet induction therapy administered at an attenuated schedule in subjects with newly diagnosed multiple myeloma (NDMM) who are eligible…
- Conditions
- Newly Diagnosed Multiple Myeloma, Multiple Myeloma, Autologous Stem Cell Transplantation
- Trial name
- NCT06348147
- Testing
- Daratumumab, Lenalidomide, Bortezomib
- Where
- United States
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Ischemic Stroke
Autologous Bone Marrow Mesenchymal Stem Cells (BMSCs) Transplantation in the Treatment of Ischemic Stroke
This study is to evaluated the safety and efficacy of BMSCs transplantation in the treatment of ischemic stroke, so as to provide a basis for future clinical application of BMSCs transplantation in the treatment of ischemic…
- Trial name
- NCT05850208
- Testing
- Transplantation of self BMSCs
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Zhujiang Hospital
Leukemia, Myeloid, Acute, Myelodysplastic Syndromes
Decitabine Maintenance for Acute Myelogenous Leukemia (AML) and Myelodysplastic Syndrome (MDS) Post Transplant
Primary: To determine the maximum tolerated dose and schedule of decitabine when administered as maintenance therapy after allogeneic hematopoietic stem cell transplantation (alloHSCT) performed for AML or high-risk MDS.
- Trial name
- AML MDS (NCT00986804)
- Testing
- Decitabine
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Washington University School of Medicine
Hematological Malignancy
Phase I of Infusion of Selected Donor NK Cells After Allogeneic Stem Cell Transplantation
The goal of our study will be to determine the clinical and biological safety of infusing immuno-selected NK (Natural Killer) CD3-/CD56+ cells, early after allogeneic transplantation with colony stimulating factor (G-CSF)…
- Trial name
- DLI-NK (NCT01853358)
- Testing
- NK Cell infusion
- Where
- France
- Volunteers
- 17 people
- Sponsor
- Institut Paoli-Calmettes
Purpura, Schoenlein-Henoch, Graft Versus Host Disease
Autologous Peripheral Blood Stem Cell Transplantation in Patients With Life Threatening Autoimmune Diseases
OBJECTIVES: I. Determine whether there is prompt engraftment after autologous peripheral blood stem cell transplantation using filgrastim (G-CSF) mobilization in patients with life threatening autoimmune diseases. II.
- Conditions
- Purpura, Schoenlein-Henoch, Graft Versus Host Disease, Anemia, Hemolytic, Autoimmune, Rheumatoid Arthritis
- Trial name
- NCT00006055
- Testing
- anti-thymocyte globulin, cyclophosphamide, cyclosporine
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Fairview University Medical Center
Sickle Cell Anemia
Bone Marrow Transplantation in Treating Children With Sickle Cell Disease
RATIONALE: Sickle cell disease is an inherited disorder in which abnormal, crescent-shaped red blood cells interfere with the ability of the blood to carry oxygen through the body and can cause severe pain, stroke, and organ…
- Trial name
- NCT00004485
- Testing
- cyclosporine, fludarabine, mycophenolate mofetil
- Where
- 2 sites in United States
- Volunteers
- 50 people
- Sponsor
- Fred Hutchinson Cancer Center
Graft Vs Host Disease, Graft-versus-host-disease
A Feasibility Study Using CLINIMACS® for Alpha/Beta T-Cell Depletion in Stem Cell Transplant
Patients in need of an allogeneic hematopoietic cell transplant (HCT) are at risk of developing graft-versus-host-disease (GVHD).
- Trial name
- NCT04337515
- Testing
- CliniMacs®
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- Christopher Dvorak
Age Related Macular Degeneration
Retinal Pigment Epithelium Safety Study for Patients in B4711001
This is a safety follow-up study. Patients enrolled in B4711001 will be followed for a further 4 years with regular visits to assess safety.
- Trial name
- NCT03102138
- Where
- United Kingdom
- Volunteers
- 10 people
- Sponsor
- Moorfields Eye Hospital NHS Foundation Trust
Leukemia, Myeloid, Acute, Myelodysplastic Syndromes
Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
This study will evaluate the safety, tolerability, and efficacy of Orca-T in participants undergoing reduced intensity or non-myeloablative allogeneic hematopoietic cell transplantation (alloHCT) for hematologic malignancies.
- Conditions
- Leukemia, Myeloid, Acute, Myelodysplastic Syndromes, Mixed Phenotype Acute Leukemia
- Trial name
- NCT07216443
- Testing
- Orca-T
- Where
- 6 sites in United States
- Volunteers
- 80 people
- Sponsor
- Orca Biosystems, Inc.
Plasma Cell Myeloma, Secondary Amyloidosis
Daratumumab After Stem Cell Transplant in Treating Patients With Multiple Myeloma
This phase II trial studies how well daratumumab after a stem cell transplant works in treating patients with multiple myeloma. Monoclonal antibodies, such as daratumumab, may kill cancer cells that are left after chemotherapy.
- Trial name
- NCT03346135
- Testing
- Autologous Hematopoietic Stem Cell Transplantation, Daratumumab, Laboratory Biomarker Analysis
- Where
- 2 sites in United States
- Volunteers
- 31 people
- Sponsor
- City of Hope Medical Center
Hematologic Malignancies
Stem Cell Transplant for Hematologic Diseases
Patients are being asked to participate in this study because they have a cancer in their blood, Fanconi's Anemia, or have been unsuccessfully treated for bone marrow failure such as Aplastic Anemia or Paroxysmal Nocturnal…
- Trial name
- HIMSUM (NCT00058825)
- Testing
- Campath 1H, Fludarabine, Stem Cell Transplant
- Where
- 2 sites in United States
- Volunteers
- 27 people
- Sponsor
- Baylor College of Medicine
Hematopoietic Stem Cell Transplantation
Fitness in Allogeneic Stem Cell Transplantation
Purpose: The primary hypothesis of this study is that the combination of interval exercise training (IET) as well as motivational accelerometry (MA) delivered both as a 5-12 week intervention that will improve cardiorespiratory…
- Trial name
- FAST (NCT02564458)
- Testing
- Interval Exercise Training/Motivational Accelerometry
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Graft Versus Host Disease, Leukemia
OTI-010 for Graft-Versus-Host Disease Prophylaxis in Treating Patients Who Are Undergoing Donor Peripheral Stem Cell Transplantation for Hematologic Malignancies
RATIONALE: OTI-010 may be effective for graft-versus-host disease prophylaxis (prevention) in patients who are undergoing donor peripheral stem cell transplantation for hematologic malignancies (cancer of the blood or bone…
- Conditions
- Graft Versus Host Disease, Leukemia, Myelodysplastic Syndromes
- Trial name
- NCT00081055
- Testing
- autologous expanded mesenchymal stem cells OTI-010, busulfan, cyclophosphamide
- Where
- United States
- Sponsor
- Mesoblast International Sàrl
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.